In network meta-analysis we synthesize all relevant available evidence about health outcomes from competing treatments. That evidence might come from different study designs and in different formats: from non-randomized studies (NRS) or randomized controlled trials (RCT) as individual participant data (IPD) or as aggregate data (AD). We set up the package crossnma to synthesize all available evidence for a binary outcome with the odds ratio as effect measure.
This document demonstrates how to use crossnma to synthesize cross-design evidence and cross-format data via Bayesian network meta-analysis and meta-regression (NMA and NMR). All models are implemented in JAGS (Plummer 2003).
We describe the workflow within the package using a worked example from a network meta-analysis of studies for treatments in relapsing remitting multiple sclerosis (RRMS). The primary outcome is the occurrence of relapses in two years (binary outcome). In the analysis, the relative effect will be the odds ratio (OR). The aim is to compare the efficacy of four treatments using the data from 6 different studies in different formats and different designs.
We first introduce the model that synthesizes studies with individual-level (IPD) or/and aggregate data (AD) ignoring their design (unadjusted synthesis). Then, we present three possible models that account for the different study designs. In the table below we set the notation that will be used in the description of the four synthesis models.
Notation | Description | Argument in crossnma.model() |
---|---|---|
i = 1, ..., npj | participant id | |
j = 1, ..., ns | study id | study |
k = 1, ..., K | treatment index | trt |
nsIPD, nsAD, nsRCT, nsNRS | the number of studies. The index refers to the design or format of the study | |
yijk | binary outcome (0/1) | outcome |
pijk | probability of the event to occur | |
rjk | the number of events per arm | outcome |
njk | the sample size per arm | n |
b | the study-specific reference | * |
ujb | The treatment effect of the study-specific reference b when xijk = x̄j = 0 | |
δjbk | log(OR) of treatment k relative to b | |
xijk | the covariate | cov1 , cov2 ,
cov3 |
x̄j | the mean covariate for study j | |
dAk | the basic parameters. Here, dAA = 0 when A is set as the reference in the network | use reference to assign the reference
treatment |
zj | study characteristics to estimate the bias probability πj | bias.covariate |
w | common inflation factor of variance for the NRS estimates | the element var.infl in
run.nrs |
ζ | common mean shift of the NRS estimates | the element mean.shift in
run.nrs |
*The study-specific reference b is assigned automatically to be the network reference for studies that have the network reference treatment. If not, it is assigned to the first alphabetically ordered treatment on the study.
We synthesize the evidence from RCT and NRS without acknowledging the differences between them. We combine the IPD data from RCT and NRS in one model and we do the same in another model with the AD information. Then, we combine the estimates from both parts as described in Section 2.5.
NMR model for IPD studies
yijk ∼ Bernoulli(pijk)
NMR model for AD studies
rjk ∼ Binomial(p.jk, njk)
First, the (network) meta-regression with only NRS data estimates the
relative treatment effects with posterior distribution of mean d̃AkNRS
and variance VAkNRS
(use run.nrs
in crossnma.model()
to control
this process). The posteriors of NRS results are then used as priors for
the corresponding basic parameters in the RCT model, dAk ∼ 𝒩(d̃AkNRS, VAkNRS).
We can adjust for potential biases associated with NRS by either
shifting the mean of the prior distribution with a bias term ζ or by dividing the prior variance
with a common inflation factor w, 0 < w < 1 controls
NRS contribution. The assigned priors become dAk ∼ 𝒩(d̃AkNRS + ζ, VAkNRS/w).
We incorporate judgments about study risk of bias (RoB) in bias-adjusted model 1 and model 2. Each judgment about the risk of bias in a study is summarized by the index Rj which takes binary values 0 (no bias) or 1 (bias). In bias-adjusted model 1, we extend the method introduced by Dias et al. (2010) by adding a treatment-specific bias term γ2, jbkRj to the relative treatment effect on both the AD and IPD parts of the model. A multiplicative model can also be employed, where treatment effects are multiplied by γ1, jbkRj. We can add either multiplicative bias effects, additive bias effects, or both (in this case, δjbk should be dropped from the additive part). The models in previous section are extended to adjust for bias as follows.
NMR model for IPD studies
NMR model for AD studies
The bias indicator Rj follows the following distribution
Rj ∼ Bernoulli(πj) The bias probabilities πj are study-specific and can be estimated in two different ways. They are either given informative beta priors (Beta(a1, a2)) that are set according to the risk of bias for each study. πj ∼ Beta(a1, a2)
The hyperparameters a1 and a2 should be chosen in a
way that reflects the risk of bias for each study. The degree of
skewness in beta distribution can be controlled by the ratio a1/a2
. When a1/a2
equals 1 (or a1 = a2),
there is no skewness in the beta distribution (the distribution is
reduced to a uniform distribution), which is appropriate for studies
with unclear risk of bias. When the ratio a1/a2
is closer to 1, the more the mean of probability of bias (expected value
of πj = a1/(a1 + a2))
gets closer to 1 and the study acquires ‘major’ bias adjustment. The
default beta priors are as follows: high bias RCT
prior.pi.high.rct='dbeta(10, 1)'
, low bias RCT
prior.pi.low.rct = 'dbeta(1, 10)'
, high bias NRS
prior.pi.high.nrs = 'dbeta(30, 1)'
and low bias NRS
prior.pi.low.nrs = 'dbeta(1, 30)'
. Alternatively, we can
use the study characteristics zj to estimate
πj through
a logistic transformation (internally coded).
We combine the multiplicative and the additive treatment-specific bias effects across studies by assuming they are exchangeable γ1, jbk ∼ 𝒩(g1, bk, τ1, γ2),γ2, jbk ∼ 𝒩(g2, bk, τ2, γ2)) or common γ1, jbk = g1, bk and γ2, jbk = g2, bk. Dias et al. (2010) proposed to model the mean bias effect (g1, bk, g2, bk) based on the treatments being compared.
where m = 1, 2. This
approach assumes a common mean bias for studies that compare active
treatments with an inactive treatment (placebo, standard or no
treatment). For active vs active comparisons, we could assume either a
zero mean bias effect or a common bias effect gmact.
The direction of bias dirbk
in studies that compare active treatments with each other should be
defined in the data. That is set to be either 0, meaning that bias
favors b over k, or 1 , meaning that k is favored to b. In crossnma.model()
,
the bias direction is specified by providing the unfavoured treatment
for each study, unfav
. To select which mean bias effect
should be applied, the user can provide the bias.group
column as data. Its values can be 0 (no bias adjustment), 1 (to assign
for the comparison mean bias effect gm) or 2 (to set
bias gmact).
Another parameterisation of the logistic model with additive bias effect is
NMR model for IPD studies
NMR model for AD studies
Then the bias-adjusted relative treatment effect (δjbkbias = δjbk + γjbk)
can be assumed exchangeable across studies δjbkbias ∼ 𝒩(gbk + dAk − dAb, τ2/qj)
or fixed as δjbkbias = gbk + dAk − dAb.
In this parameterisation, instead of assigning prior to the
between-study heterogeneity in bias effect τγ, we model the
RoB weight qj = τ2/(τ2 + τγ2)
for each study. This quantity 0 < qj < 1
quantifies the proportion of the between-study heterogeneity that is not
explained by accounting for risk of bias. The values of v determine the extent studies at
high risk of bias will be down-weighted on average. Setting v = 1 gives E(qj) = v/(v + 1) = 0.5,
which means that high risk of bias studies will be penalized by 50% on
average. In crossnma.model()
, the user can assign the
average down-weight E(qj)
to the argument down.wgt
.
Another way to incorporate the RoB of the study is by replacing δjbk by a “bias-adjusted” relative treatment effect θjbk. Then θjbk is modeled with a bimodal normal distribution as described in Section 2.5. For more details see Verde (2020).
NMR model for IPD studies
NMR model for AD studies
where the bias-adjusted relative treatment effect (θjk) are modeled via random-effects model with a mixture of two normal distributions.
θjbk ∼ (1 − πj)𝒩(dAk − dAb, τ2) + πj𝒩(dAk − dAb + γjbk, τ2 + τγ2)
Alternatively, we can summarize these relative effects assuming a common-effect model
θjbk = dAk − dAb + πjγjbk
The table below summarizes the different assumptions implemented in the package about combining the parameters in the models described above.
Parameter | Assumptions | Argument in crossnma.model() |
---|---|---|
Relative treatment effect (δjbk) | Random-effects: δjbk ∼ 𝒩(dAk − dAb, τ2) | trt.effect='random' |
Common-effect: δjbk = dAk − dAb | trt.effect='common' |
|
Covariate effect (β0j) | Independent effects: β0j ∼ 𝒩(0, 102) | reg0.effect='independent' |
Random-effects: β0j ∼ 𝒩(B0, τ02) | reg0.effect='random' |
|
Within-study covariate-treatment | Independent effects: β1, jbkW ∼ 𝒩(0, 102) | regw.effect='independent' |
interaction (β1, jbkW) | Random-effects: β1, jbkW ∼ 𝒩(B1, AkW − B1, AbW, τW2) | regw.effect='random' |
Common-effect: β1, jbkW = B1, AkW − B1, AbW | regw.effect='common' |
|
Between-study covariate-treatment | Independent effects: β1, jbkB ∼ 𝒩(0, 102) | regb.effect='independent' |
interaction (β1, jbkB) | Random-effects: β1, jbkB ∼ 𝒩(B1, AkB − B1, AbB, τB2) | regb.effect='random' |
Common-effect: β1, jbkB = B1, AkB − B1, AbB | regb.effect='common' |
|
Bias effect (γm, jbk), m = 1, 2 | Random-effects: γm, jbk ∼ 𝒩(gm, bk, τm, γ2) | bias.effect='random' |
Common-effect: γm, jbk = gm, bk | bias.effect='common' |
|
Mean bias effect gm, bk | The treatment k is active. gm, bk = gm (b inactive), gm, bk = 0 (b active & no bias) gm, bk = gmact(b active & bias) | unfav=0 , bias.group=1
unfav=1 , bias.group=0 unfav=1 ,
bias.group=2 |
Bias probability (πj) | πj ∼ Beta(a1, a2) | pi.high.nrs , pi.low.nrs ,
pi.high.rct , pi.low.rct |
πj = e + fzj | bias.covariate |
The data we use are fictitious but resemble real RCTs with IPD and
aggregate data included in Tramacere and
Filippini (2015). The studies provide either individual
participant data ipddata
(3 RCTs and 1 cohort study) or
aggregate data stddata
(2 RCTs). In total, four drugs are
compared which are anonymized.
The ipddata
contains 1944 participants / rows. We
display the first few rows of the data set:
dim(ipddata)
#> [1] 1944 10
head(ipddata)
#> id relapse treat design age sex rob unfavored bias.group year
#> 1 1 0 D rct 22 1 low 1 1 2002
#> 2 1 0 D rct 31 1 low 1 1 2002
#> 3 1 0 D rct 34 1 low 1 1 2002
#> 4 1 0 D rct 38 0 low 1 1 2002
#> 5 1 0 D rct 46 0 low 1 1 2002
#> 6 1 0 D rct 45 0 low 1 1 2002
For each participant, we have information for the
outcome
relapse (0 = no, 1 = yes), the treatment label
treat
, the age
(in years) and sex
(0 = female, 1 = male) of the participant. The following columns are set
on study-level (it is repeated for each participant in each study): the
id
, the design
of the study (needs to be
either "rct"
or "nrs"
), the risk of bias
rob
on each study (can be set as low, high or unclear), the
year
of publication, the bias.group
for the
study comparison and the study unfavoured treatment
unfavored
.
The aggregate meta-analysis data must be in long arm-based format with the exact same variable names and an additional variable with the sample sizes:
There are two steps to run the NMA/NMR model. The first step is to
create a JAGS model using crossnma.model()
which produces
the JAGS code and the data. In the second step, the output of that
function will be used in crossnma()
to run the analysis
through JAGS.
We start by providing the essential variables which - as stated
earlier - must have equal names in both data sets. Next, we give the
names of the datasets on participant-level (argument
prt.data
) and aggregate data (argument
std.data
). By default, binary data is analyzed using the
odds ratio as a summary measure (sm = "OR"
). The
reference
treatment can be assigned which by default is the
first treatment (here: drug A). By default
(trt.effect = "random"
), we are assigning a normal
distribution to each relative treatment effect to allow the synthesis
across studies, see the table in Section 2.1. The different designs; RCT
and NRS are combined with the information taken at face-value as
method.bias = "naive"
.
Optionally, we can specify a prior to the common heterogeneity of the
treatment effect across studies. We indicate that distribution in the
argument prior.tau.trt = "dunif(0, 3)"
.
Finally, we calculate the Surface Under the Cumulative Ranking
(SUCRA) in order to rank the treatments. It is essential to specify
argument small.values
to get the correct ranking. For the
RRMS studies, a small number of relapses is desirable.
# JAGS model: code + data
mod1 <- crossnma.model(treat, id, relapse, n, design,
prt.data = ipddata, std.data = stddata,
#---------- bias adjustment ----------
method.bias = "naive",
#---------- assign a prior ----------
prior.tau.trt = "dunif(0, 3)",
#---------- SUCRA ----------
sucra = TRUE, small.values = "desirable"
)
#> Both designs are combined naively without acknowledging design differences.
The network should be checked for its connectivity before running the analysis. This is a vital step as the model will run even if the network is not connected.
netgraph(mod1, cex.points = n.trts, adj = 0.5, plastic = FALSE,
number = TRUE, pos.number.of.studies = c(0.5, 0.4, 0.5, 0.5, 0.6, 0.5))
We are using argument number.of.studies = TRUE
in order
to print the number of studies in each direct comparison. The position
of the number of studies is set by argument
pos.number.of.studies
.
Next, we fit the NMA model using crossnma()
. We change
the default settings for the number of iterations, burn-in and
thinning.
# Run JAGS
jagsfit1 <- crossnma(mod1, n.iter = 5000, n.burnin = 2000, thin = 1)
jagsfit1
#> Mean SD 2.5% 50% 97.5% Rhat n.eff
#> exp(d.A) . . . . . . .
#> exp(d.B) 0.470 0.194 0.322 0.468 0.692 1.009 865
#> exp(d.C) 0.629 0.211 0.416 0.629 0.944 1.015 582
#> exp(d.D) 0.341 0.265 0.202 0.341 0.571 1.004 671
#> tau 0.188 0.182 0.002 0.140 0.673 1.044 241
#> SUCRA.A 0.006 0.047 0.000 0.000 0.000 1.010 2547
#> SUCRA.B 0.680 0.153 0.333 0.667 1.000 1.000 1349
#> SUCRA.C 0.368 0.128 0.333 0.333 0.667 1.004 1382
#> SUCRA.D 0.947 0.142 0.667 1.000 1.000 1.000 1013
#> Mean and quantiles are exponentiated
By default (argument backtransf = TRUE
), estimated odds
ratios, i.e., exp(d.B), exp(d.C) and exp(d.D), are printed. The value of
tau refers to the estimates of the heterogeneity standard deviation in
the relative treatment effects d.B, d.C and d.D across studies. The
SUCRA values are probabilities with treatment D being notably superior
to the other treatments.
We summarize the estimated parameters (argument
backtransf = FALSE
) in the following table.
Mean | SD | 2.5% | 50% | 97.5% | Rhat | n.eff | |
---|---|---|---|---|---|---|---|
d.A | . | . | . | . | . | . | . |
d.B | -0.755 | 0.194 | -1.133 | -0.759 | -0.368 | 1.009 | 865 |
d.C | -0.463 | 0.211 | -0.878 | -0.463 | -0.058 | 1.015 | 582 |
d.D | -1.076 | 0.265 | -1.602 | -1.077 | -0.560 | 1.004 | 671 |
tau | 0.188 | 0.182 | 0.002 | 0.140 | 0.673 | 1.044 | 241 |
SUCRA.A | 0.006 | 0.047 | 0.000 | 0.000 | 0.000 | 1.010 | 2547 |
SUCRA.B | 0.680 | 0.153 | 0.333 | 0.667 | 1.000 | 1.000 | 1349 |
SUCRA.C | 0.368 | 0.128 | 0.333 | 0.333 | 0.667 | 1.004 | 1382 |
SUCRA.D | 0.947 | 0.142 | 0.667 | 1.000 | 1.000 | 1.000 | 1013 |
We need also to assess the convergence of the MCMC chains either by checking the Gelman and Rubin statistic, Rhat (it should be approximately 1) in the table above or visually inspect the trace plot.
In this part, we set argument cov1 = age
to run a NMR
model with one covariate. Again, datasets ipddata
and
stddata
must use the same variable name.
# JAGS model: code + data
mod2 <- crossnma.model(treat, id, relapse, n, design,
prt.data = ipddata, std.data = stddata,
#---------- bias adjustment ----------
method.bias = "naive",
#---------- meta-regression ----------
cov1 = age,
split.regcoef = FALSE
)
#> Both designs are combined naively without acknowledging design differences.
We could add two more covariates to the NMR model using arguments
cov2
and cov3
.
The MCMC is run under the same set up as in the network meta-analysis.
and the output table is presented below
Mean | SD | 2.5% | 50% | 97.5% | Rhat | n.eff | |
---|---|---|---|---|---|---|---|
d.A | . | . | . | . | . | . | . |
d.B | -0.899 | 0.347 | -1.583 | -0.894 | -0.239 | 1.001 | 97 |
d.C | -0.468 | 0.377 | -1.199 | -0.464 | 0.283 | 1.006 | 127 |
d.D | -0.975 | 0.493 | -1.896 | -0.987 | 0.135 | 1.018 | 103 |
b_1 | 0.000 | 0.067 | -0.116 | 0.000 | 0.106 | 1.074 | 3300 |
tau | 0.220 | 0.193 | 0.008 | 0.170 | 0.726 | 1.024 | 219 |
tau.b_1 | 0.056 | 0.101 | 0.001 | 0.023 | 0.412 | 1.098 | 112 |
Now, we additionally estimate b_1 which indicates the mean effect of age and tau.b_1 which refers to the heterogeneity standard deviation in the effect of age across studies. Here, we obtain a single estimate because we choose to not split the within- and between-study age coefficients (β1, jbkw = β1, jbkB = β1, jbk) to improve the convergence of MCMC.
The league table summarizes the relative effect with the 95% credible interval of each treatment on the top compared to the treatment on the left. All estimates are computed for participant age 38. We can display the table in wide format
league(jagsfit2, cov1.value = 38, digits = 2)
#>
#> A 0.41 (0.21 to 0.79) 0.63 (0.30 to 1.33)
#> 2.44 (1.27 to 4.87) B 1.51 (0.75 to 3.38)
#> 1.59 (0.75 to 3.32) 0.66 (0.30 to 1.33) C
#> 2.68 (0.87 to 6.66) 1.11 (0.34 to 2.79) 1.67 (0.56 to 4.57)
#>
#> 0.37 (0.15 to 1.14)
#> 0.90 (0.36 to 2.95)
#> 0.60 (0.22 to 1.79)
#> D
or in long format
league(jagsfit2, cov1.value = 38, digits = 2, direction = "long")
#> Treatment Comparator median 2.5% 97.5%
#> B A 0.41 0.21 0.79
#> C A 0.63 0.30 1.33
#> D A 0.37 0.15 1.14
#> A B 2.44 1.27 4.87
#> C B 1.51 0.75 3.38
#> D B 0.90 0.36 2.95
#> A C 1.59 0.75 3.32
#> B C 0.66 0.30 1.33
#> D C 0.60 0.22 1.79
#> A D 2.68 0.87 6.66
#> B D 1.11 0.34 2.79
#> C D 1.67 0.56 4.57
To run NMA with a prior constructed from NRS, two additional
arguments are needed: we indicate using NRS as a prior by setting
method.bias = "prior"
. That means that the model runs
internally NMA with only NRS data which are then used to construct
informative priors. This requires defining MCMC settings (the number of
adaptations, iterations, burn-ins, thinning and chains) in the arguments
starts with run.nrs
.
In this method, the prior for the basic parameters is set to a normal
distribution. For basic parameters not examined in the NRS, the code
sets a minimally informative prior d~dnorm(0, {15*ML}^2)
,
where ML is the largest maximum likelihood estimates of all relative
treatment effects in all studies. To account for possible bias, the
means of the distribution can be shifted by
run.nrs.mean.shift
and/or the variance can be inflated by
run.nrs.var.infl
to control the influence of NRS on the
final estimation.
# JAGS model: code + data
mod3 <- crossnma.model(treat, id, relapse, n, design,
prt.data = ipddata, std.data = stddata,
reference = "D",
#---------- meta-regression ----------
cov1 = age,
split.regcoef = FALSE,
#---------- bias adjustment ----------
method.bias = "prior",
run.nrs.trt.effect= "common",
run.nrs.var.infl = 0.6, run.nrs.mean.shift = 0,
run.nrs.n.iter = 10000, run.nrs.n.burnin = 4000,
run.nrs.thin = 1, run.nrs.n.chains = 2
)
The heat plot summarizes the relative effect with the 95% credible interval of each treatment on the top compared to the treatment on the left. All estimates are computed for participant age 38.
In this part, the overall relative treatment effects are estimated from both NRS and RCT with adjustment to study-specific bias.
To fit the model, we set method.bias = "adjust1"
and we
need to provide the bias variable bias = rob
in the
datasets. The direction of bias is determined by the column
unfav = unfavored
which indicates the unfavoured treatment.
The mean bias effect can be indicated by bias.group
, 0 (bias.group = 0
), g (bias.group = 1
) or
gact
(bias.group = 2
). By default, the effect of bias is assumed
to be additive bias.type = "add"
and equal across studies
bias.effect = "common"
. We also use the year
of study publication to estimate the study-probability of bias,
bias.covariate = year
.
# JAGS model: code + data
mod4 <- crossnma.model(treat, id, relapse, n, design,
prt.data = ipddata, std.data = stddata,
#---------- bias adjustment ----------
method.bias = "adjust1",
bias.type = "add",
bias.effect = "common",
bias = rob,
unfav = unfavored,
bias.group = bias.group,
bias.covariate = year
)
#> Bias effect is assumed common across studies
The results are presented below
Mean | SD | 2.5% | 50% | 97.5% | Rhat | n.eff | |
---|---|---|---|---|---|---|---|
d.A | . | . | . | . | . | . | . |
d.B | -0.767 | 0.213 | -1.189 | -0.774 | -0.310 | 1.012 | 1343 |
d.C | -0.474 | 0.224 | -0.933 | -0.473 | -0.035 | 1.010 | 596 |
d.D | -1.073 | 0.280 | -1.641 | -1.070 | -0.543 | 1.016 | 1028 |
g | -0.076 | 19.786 | -38.139 | -0.318 | 39.382 | 1.000 | 6673 |
tau | 0.225 | 0.191 | 0.012 | 0.175 | 0.717 | 1.051 | 196 |
The parameter g
refers to the mean bias effect, common
for all studies.
The arguments for method.bias = "adjust2"
are similar to
the ones used before in method.bias = "adjust1"
.
# JAGS model: code + data
mod5 <- crossnma.model(treat, id, relapse, n, design,
prt.data = ipddata, std.data = stddata,
#---------- bias adjustment ----------
method.bias = "adjust2",
bias.type = "add",
bias = rob,
unfav = unfavored,
bias.group = bias.group
)
Mean | SD | 2.5% | 50% | 97.5% | Rhat | n.eff | |
---|---|---|---|---|---|---|---|
d.A | . | . | . | . | . | . | . |
d.B | -0.755 | 0.285 | -1.297 | -0.776 | -0.163 | 1.009 | 387 |
d.C | -0.482 | 0.262 | -1.074 | -0.461 | 0.045 | 1.010 | 420 |
d.D | -1.094 | 0.359 | -1.913 | -1.070 | -0.417 | 1.025 | 585 |
g | 0.009 | 0.366 | -0.747 | 0.029 | 0.721 | 1.049 | 238 |
tau | 0.291 | 0.247 | 0.001 | 0.225 | 0.941 | 1.018 | 100 |